Canaccord lowered the firm’s price target on Nevro (NVRO) to $4 from $7 and keeps a Hold rating on the shares. Canaccord said they are bullish on the Med-Tech sector heading into 2025 as they expect investor interest to increase given smid-cap valuations continue to remain depressed while M&A has picked up and the IPO market seems to have opened. They highlight how AI is changing the space and are seeing continued interest in value-based care in the US, and believe that med-tech is well positioned to help drive the trend for improving patient outcomes while also reducing overall costs.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO:
- Nevro resumed with an Equal Weight at Wells Fargo
- Nevro downgraded to Underweight from Equal Weight at Morgan Stanley
- Nevro announces publication of new data on Nevro1 SI Joint Fusion System
- Nevro Corp. Reports Strong Q3 2024 Financial Performance
- Nevro Corp’s Market Cap Challenges: Impairment Risks and Investor Concerns